DE2202441C3 - - Google Patents

Info

Publication number
DE2202441C3
DE2202441C3 DE2202441A DE2202441A DE2202441C3 DE 2202441 C3 DE2202441 C3 DE 2202441C3 DE 2202441 A DE2202441 A DE 2202441A DE 2202441 A DE2202441 A DE 2202441A DE 2202441 C3 DE2202441 C3 DE 2202441C3
Authority
DE
Germany
Prior art keywords
barbituric acid
substituted
acid derivative
unsubstituted
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
DE2202441A
Other languages
German (de)
English (en)
Other versions
DE2202441A1 (de
DE2202441B2 (de
Inventor
Sidney Livingstone N.J. Spector (V.St.A.)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of DE2202441A1 publication Critical patent/DE2202441A1/de
Publication of DE2202441B2 publication Critical patent/DE2202441B2/de
Application granted granted Critical
Publication of DE2202441C3 publication Critical patent/DE2202441C3/de
Granted legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/948—Sedatives, e.g. cannabinoids, barbiturates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/815—Test for named compound or class of compounds
    • Y10S436/816—Alkaloids, amphetamines, and barbiturates
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/823—Immunogenic carrier or carrier per se
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Anesthesiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE2202441A 1971-08-24 1972-01-19 Barbitursäureantigene und spezifische Antikörper hierfür Granted DE2202441B2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17451771A 1971-08-24 1971-08-24

Publications (3)

Publication Number Publication Date
DE2202441A1 DE2202441A1 (de) 1973-03-01
DE2202441B2 DE2202441B2 (de) 1980-04-10
DE2202441C3 true DE2202441C3 (enExample) 1981-01-15

Family

ID=22636461

Family Applications (1)

Application Number Title Priority Date Filing Date
DE2202441A Granted DE2202441B2 (de) 1971-08-24 1972-01-19 Barbitursäureantigene und spezifische Antikörper hierfür

Country Status (5)

Country Link
US (1) US3766162A (enExample)
JP (1) JPS5928864B2 (enExample)
CA (1) CA956889A (enExample)
DE (1) DE2202441B2 (enExample)
GB (1) GB1327545A (enExample)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL171930C (nl) * 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US4022878A (en) * 1972-05-15 1977-05-10 Biological Developments, Inc. Methods and compounds for producing specific antibodies
US3995021A (en) * 1972-05-15 1976-11-30 Biological Developments, Inc. Antigens of 5,5'alkylphenyl barbituric acids and related hydantoin compounds
US3856469A (en) * 1973-01-02 1974-12-24 Syva Corp Interferant removal from amphetamine immunoassay
US3998943A (en) * 1973-10-02 1976-12-21 Syva Company Double receptor fluorescent immunoassay
US3979507A (en) * 1973-11-23 1976-09-07 Wilson Pharmaceutical & Chemical Corporation Diagnostic system for organ abnormalities
US3963691A (en) * 1974-10-07 1976-06-15 Merck & Co., Inc. Synthetic antigens of luteinizing hormone releasing hormone
US3952091A (en) * 1974-10-23 1976-04-20 Hoffmann-La Roche Inc. Simultaneous multiple radioimmunoassay
US4036823A (en) * 1975-04-28 1977-07-19 Biological Developments, Inc. Barbituric acid antigenic conjugates, their preparation, antibodies and use
USRE32696E (en) * 1975-09-04 1988-06-14 Akzona Incorporated Enzymatic immunological method for determination of antigens and antibodies
US4101549A (en) * 1976-05-26 1978-07-18 Hoffmann-La Roche Inc. Aminophenyl esters of 5-carboxyalkyl barbituric acids
JPS5341420A (en) * 1976-09-29 1978-04-14 Mochida Pharm Co Ltd Immunochemically measuring methoa of hapten
US4816253A (en) * 1977-12-08 1989-03-28 Likhite Vilas V Novel mutant strain of Listeria monocytogenes and its use in production of IgM antibodies and as an immunotherapeutic agent
US4567041A (en) * 1977-12-08 1986-01-28 Likhite Vilas V Mutant strain of Listeria monocytogenes and its use in production of IgM antibodies and as an immunotherapeutic agent
JPS55500053A (enExample) * 1978-01-16 1980-01-31
US4347312A (en) * 1980-03-20 1982-08-31 Research Triangle Institute Detection of antibiotics in milk
US4645828A (en) 1984-03-23 1987-02-24 Oncogen Platelet related growth regulator
IE64785B1 (en) 1985-04-08 1995-09-06 Genetic Systems Corp Expression of immunologically reactive viral proteins
US4721704A (en) * 1986-05-09 1988-01-26 Peninsula Laboratories, Inc. Potent synthetic atrial peptide analogs
US5099020A (en) * 1989-11-27 1992-03-24 Abbott Laboratories Barbiturate assay compositions and methods
US6699474B1 (en) * 1990-08-20 2004-03-02 Erich Hugo Cerny Vaccine and immunserum against drugs of abuse
CH678394A5 (enExample) * 1990-08-22 1991-09-13 Cerny Erich H
US5414085A (en) * 1992-04-06 1995-05-09 Biosite Diagnostics, Inc. Barbiturate derivatives and protein and polypeptide barbiturate derivative conjugates and labels
US6953573B1 (en) 1993-03-17 2005-10-11 University Of Washington Compounds for eliciting or enhancing immune reactivity to HER-2/neu protein for prevention or treatment of malignancies in which the HER-2/neu oncogene is associated
US5801005A (en) * 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
US5869445A (en) * 1993-03-17 1999-02-09 University Of Washington Methods for eliciting or enhancing reactivity to HER-2/neu protein
AU5374996A (en) * 1995-03-31 1996-10-16 Cantab Pharmaceuticals Research Limited Hapten-carrier conjugates for use in drug-abuse therapy
US5840307A (en) * 1995-03-31 1998-11-24 Immulogic Pharmacuetical Corp. Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation
US5876727A (en) * 1995-03-31 1999-03-02 Immulogic Pharmaceutical Corporation Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same
US6942862B2 (en) * 1996-04-01 2005-09-13 University Of Washington Methods and compositions to generate immunity in humans against self tumor antigens by immunization with homologous foreign proteins
US6232082B1 (en) 1998-12-01 2001-05-15 Nabi Hapten-carrier conjugates for treating and preventing nicotine addiction
US6696254B2 (en) 2001-11-21 2004-02-24 Kimberly-Clark Worldwide, Inc. Detection and identification of enteric bacteria
EP3031910B1 (en) 2002-02-21 2017-08-16 Institute Of Virology Mn/ca ix-specific monoclonal antibodies generated from mn/ca ix-deficient mice and methods of use
WO2003089659A1 (en) * 2002-04-16 2003-10-30 The Regents Of The University Of California Methods or renal cell carcinoma prognosis and treatment selection with carbonic anhydrase ix
EP1649282A4 (en) * 2003-07-07 2007-08-29 Webb Waring Inst PROCESS FOR PREDICTING THE DEVELOPMENT OF AUTOIMMUNE DISEASES AND TREATMENT THEREOF
SG148143A1 (en) 2003-11-04 2008-12-31 Novartis Vaccines & Diagnostic Antagonist anti-cd40 monoclonal antibodies and methods for their use
PL1680141T3 (pl) 2003-11-04 2011-04-29 Novartis Vaccines & Diagnostics Inc Sposoby leczenia guzów litych wykazujących ekspresję antygenu powierzchniowego CD40
DK1684805T3 (da) 2003-11-04 2010-10-04 Novartis Vaccines & Diagnostic Anvendelse af antagonist anti-CD40-monoklonale antistoffer til behandling af multipel myeloma
EP2243491A1 (en) 2003-11-04 2010-10-27 Novartis Vaccines and Diagnostics, Inc. Use of antagonist anti-CD40 monoclonal antibodies for treatment of chronic lymphocytic leukemia
US7022492B2 (en) * 2003-12-15 2006-04-04 Dade Behring Inc. Ecstasy haptens and immunogens
US6991911B2 (en) * 2003-12-15 2006-01-31 Dade Behring Inc. Assay for entactogens
US20050130243A1 (en) * 2003-12-15 2005-06-16 Zheng Yi F. Assay for entactogens
US7115383B2 (en) * 2004-03-22 2006-10-03 Dade Behring Inc. Assays for amphetamine and methamphetamine
US7037669B2 (en) * 2004-03-22 2006-05-02 Dade Behring Inc. Assays for amphetamine and methamphetamine using stereospecific reagents
EP1809765A2 (en) * 2004-11-04 2007-07-25 Roche Diagnostics GmbH Classification of acute myeloid leukemia
US7842794B2 (en) 2004-12-17 2010-11-30 Roche Molecular Systems, Inc. Reagents and methods for detecting Neisseria gonorrhoeae
PL1889065T3 (pl) 2005-05-18 2013-12-31 Novartis Ag Metody diagnostyki i leczenia chorób posiadających składnik autoimmunologiczny i/lub zapalny
US8945564B2 (en) 2006-04-21 2015-02-03 Novartis Ag Antagonist anti-CD40 antibody pharmaceutical compositions
GB0700133D0 (en) 2007-01-04 2007-02-14 Humabs Llc Human cytomegalovirus neutralising antibodies and use thereof
US8124093B2 (en) 2008-07-16 2012-02-28 Institute For Research In Biomedicine Human cytomegalovirus neutralizing antibodies and use thereof
JP5475774B2 (ja) 2008-07-16 2014-04-16 インスティテュート フォー リサーチ イン バイオメディシン ヒトサイトメガロウイルス中和抗体およびその使用
ES2662519T3 (es) * 2008-07-25 2018-04-06 Institute For Research In Biomedicine Anticuerpos neutralizantes contra el virus de la gripe A y usos de estos
US8871207B2 (en) 2008-07-25 2014-10-28 Humabs, LLC Neutralizing anti-influenza A virus antibodies and uses thereof
US20130183326A9 (en) 2009-11-20 2013-07-18 St. Jude Children's Research Hospital Methods and compositions for modulating the activity of the interleukin-35 receptor complex
WO2012075111A1 (en) 2010-11-30 2012-06-07 Novartis Ag Uses of anti-cd40 antibodies in combination therapy for b cell-related cancers
CA2841551C (en) 2011-07-18 2020-07-28 Institute For Research In Biomedicine Neutralizing anti-influenza a virus antibodies and uses thereof
EP2828293B1 (en) 2012-03-20 2017-10-25 Humabs Biomed S.A. Antibodies that neutralize rsv, mpv and pvm and uses thereof
JP6535675B2 (ja) 2013-10-02 2019-06-26 メディミューン，エルエルシー 抗ａ型インフルエンザ抗体の中和及びその使用
CN113563462B (zh) 2014-07-15 2024-08-13 免疫医疗有限责任公司 中和抗乙型流感抗体及其用途
US20170296650A1 (en) 2014-10-08 2017-10-19 Novartis Ag Combination of human cytomegalovirus neutralizing antibodies
WO2016075546A2 (en) 2014-11-14 2016-05-19 Antonio Lanzavecchia Antibodies that neutralize ebola virus and uses thereof
LT3220947T (lt) 2014-11-18 2020-12-28 Humabs Biomed S.A. Antikūnai, galintys neutralizuoti pasiutligės virusą ir kitus lisavirusus bei jų panaudojimas
MX389708B (es) 2015-06-01 2025-03-20 Medimmune Llc Neutralizacion de moleculas de union anti-influenza y usos de las mismas.
EP3313871A1 (en) 2015-06-26 2018-05-02 Institute for Research in Biomedicine Proteins comprising a mutated lair-1 fragment and uses thereof
WO2017059878A1 (en) 2015-10-07 2017-04-13 Humabs Biomed Sa Antibodies that potently neutralize hepatitis b virus and uses thereof
SG11201805001UA (en) 2016-01-13 2018-07-30 Medimmune Llc Method of treating influenza a
WO2018010789A1 (en) 2016-07-13 2018-01-18 Humabs Biomed Sa Novel antibodies specifically binding to zika virus epitopes and uses thereof
SG11201909265QA (en) 2017-04-19 2019-11-28 Inst Res Biomedicine Plasmodium sporozoite npdp peptides as vaccine and target novel malaria vaccines and antibodies binding to
WO2019042555A1 (en) 2017-08-31 2019-03-07 Humabs Biomed Sa MULTISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO ZIKA VIRUS EPITOPES AND USES THEREOF
WO2020132091A2 (en) 2018-12-19 2020-06-25 Humabs Biomed Sa Antibodies that neutralize hepatitis b virus and uses thereof
WO2021042000A1 (en) 2019-08-29 2021-03-04 Vir Biotechnology, Inc. Antibody compositions and methods for treating hepatitis b virus infection
CN112898414B (zh) 2019-12-04 2024-05-10 珠海泰诺麦博制药股份有限公司 抗人巨细胞病毒抗体及其用途
CN116390943A (zh) 2020-06-24 2023-07-04 维尔生物科技有限公司 工程化乙型肝炎病毒中和抗体和其用途
US12492372B2 (en) 2020-11-24 2025-12-09 Monash University Induced stem cells
US20240092872A1 (en) 2021-01-26 2024-03-21 Vir Biotechnology, Inc. Compositions and methods for treating hepatitis b virus infection
JP2024509973A (ja) 2021-03-10 2024-03-05 マビュロン アーゲー Ｔｄｐ－４３に対する抗体およびその使用方法

Also Published As

Publication number Publication date
JPS5928864B2 (ja) 1984-07-16
US3766162A (en) 1973-10-16
CA956889A (en) 1974-10-29
DE2202441A1 (de) 1973-03-01
DE2202441B2 (de) 1980-04-10
JPS4828623A (enExample) 1973-04-16
GB1327545A (en) 1973-08-22

Similar Documents

Publication Publication Date Title
DE2202441C3 (enExample)
DE69332988T2 (de) Reagenzien zum Nachweis und zur Quantifizierung von Thyroxin in flüssigen Proben
DE3785038T2 (de) Monoklonale antikoerper gegen nicht reduzierte, nicht enzymatisch glykolysierte proteine.
DE69218981T2 (de) Verfahren zum Nachweis freier IGF-I, IGF-II, und GH Spiegel in Körperflüssigkeiten
DE2805663C3 (enExample)
DE2953449A1 (de) Verfahren und ausruestung fuer die enzym-immunoassay von biologischen substanzen
EP0013930B1 (de) Immunogen, Antikörper für ein Thymus-Hormon, markiertes Thymus-Hormon und Verfahren zur Bestimmung dieses Thymushormons
DE2901218A1 (de) Ung von theophyllin
DE2653032A1 (de) Radioimmun-nachweisverfahren fuer ein schilddruesenhormon und dafuer geeignetes reagens
DE69132122T2 (de) Reinigung von cytokeratinfragmenten
DE3218312C2 (de) Monoklonale Antikörper, Hybridoma-Zellklone, Verfahren zu ihrer Herstellung und ihre Verwendung zur Erkennung von Brustkrebs und maligner Lymphogranulomatose
DE2608096C2 (enExample)
DE2716536C2 (de) Methadon-Antigene und Verfahren zur Herstellung dieser
DE1961541A1 (de) Immunologisches Indikatorreagens
DE60035267T2 (de) Verfahren zur analyse der menge an intraabdominalem fettgewebe
EP0183901B1 (de) Bifunktionelle Haptene, Verfahren zu ihrer Herstellung und ihre Verwendung
DE2548196A1 (de) Antigene auf basis von methaqualon- hapten sowie deren verwendung
DE2310280A1 (de) Tubocurarin-antigene
DE3025226C2 (de) Pterinderivate und ihre Verwendung zur radioimmunologischen Bestimmung von Pterinen
EP0124779A2 (de) Radioimmunverfahren für Thymosin beta 4
EP0015473A1 (de) Verfahren zum Immobilisieren von Zellen
DE3887727T2 (de) Partikelstabilisierte Epitope zur Standardisierung und Kontrolle von Immuntests.
DE2714751C2 (enExample)
DE3509958A1 (de) Monoklonale antikoerper gegen atriale, natriuretische peptide vom menschen
DE2738156A1 (de) Bestimmung von catecholaminen

Legal Events

Date Code Title Description
OD Request for examination
C3 Grant after two publication steps (3rd publication)
8339 Ceased/non-payment of the annual fee